AR070964A1 - Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento - Google Patents
Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimentoInfo
- Publication number
- AR070964A1 AR070964A1 ARP090100819A ARP090100819A AR070964A1 AR 070964 A1 AR070964 A1 AR 070964A1 AR P090100819 A ARP090100819 A AR P090100819A AR P090100819 A ARP090100819 A AR P090100819A AR 070964 A1 AR070964 A1 AR 070964A1
- Authority
- AR
- Argentina
- Prior art keywords
- ziprasidone
- pharmaceutical form
- form comprises
- human
- process according
- Prior art date
Links
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 19
- 229960000607 ziprasidone Drugs 0.000 title abstract 19
- 238000000034 method Methods 0.000 title abstract 9
- 208000015114 central nervous system disease Diseases 0.000 abstract 3
- 241000282412 Homo Species 0.000 abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000008247 solid mixture Substances 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3494708P | 2008-03-07 | 2008-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070964A1 true AR070964A1 (es) | 2010-05-19 |
Family
ID=40720011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100819A AR070964A1 (es) | 2008-03-07 | 2009-03-06 | Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110002989A1 (https=) |
| EP (1) | EP2280711A1 (https=) |
| JP (1) | JP2009215293A (https=) |
| KR (1) | KR20100131477A (https=) |
| CN (1) | CN102014910A (https=) |
| AR (1) | AR070964A1 (https=) |
| AU (1) | AU2009220925A1 (https=) |
| BR (1) | BRPI0909818A2 (https=) |
| CA (1) | CA2719115A1 (https=) |
| IL (1) | IL207792A0 (https=) |
| MX (1) | MX2010009844A (https=) |
| RU (1) | RU2010135831A (https=) |
| TW (1) | TW200950783A (https=) |
| WO (1) | WO2009109844A1 (https=) |
| ZA (1) | ZA201005905B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010082855A1 (en) * | 2009-01-15 | 2010-07-22 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation |
| US9510148B2 (en) * | 2009-03-03 | 2016-11-29 | Mobilitie, Llc | System and method for wireless communication to permit audience participation |
| CN105492007A (zh) * | 2013-05-03 | 2016-04-13 | 欣达克斯制药公司 | 癌症治疗方法 |
| CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| EP3076951B1 (en) * | 2013-12-05 | 2020-09-30 | Celal Albayrak | Process for the production of drug formulations for oral administration |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US10474345B2 (en) * | 2014-04-04 | 2019-11-12 | Shawn SHEY | User interfaces and methods for displaying content |
| RU2017106029A (ru) * | 2014-09-19 | 2018-10-19 | Дзе Проктер Энд Гэмбл Компани | Способ изготовления ядра частиц, содержащего покрытие активным веществом |
| ES3063790T3 (en) | 2015-06-09 | 2026-04-20 | Lonza Sales Ag | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| US11154510B2 (en) | 2015-06-11 | 2021-10-26 | Alrise Biosystems Gmbh | Process for the preparation of drug loaded microparticles |
| CN107714669A (zh) * | 2016-08-11 | 2018-02-23 | 广东东阳光药业有限公司 | 齐拉西酮缓释剂及其制备方法 |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002309172A1 (en) * | 2001-06-22 | 2003-01-08 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| KR20090080143A (ko) * | 2003-09-02 | 2009-07-23 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
| US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
| EP1703898A2 (en) * | 2003-12-31 | 2006-09-27 | Alpharma, Inc. | Ziprasidone formulations |
| WO2005123086A2 (en) * | 2004-06-11 | 2005-12-29 | Dr. Reddy's Laboratories Ltd. | Ziprasidone dosage form |
| CA2613474A1 (en) * | 2005-06-20 | 2007-03-08 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds |
-
2009
- 2009-03-04 KR KR1020107022343A patent/KR20100131477A/ko not_active Ceased
- 2009-03-04 CA CA2719115A patent/CA2719115A1/en not_active Abandoned
- 2009-03-04 RU RU2010135831/15A patent/RU2010135831A/ru not_active Application Discontinuation
- 2009-03-04 WO PCT/IB2009/000442 patent/WO2009109844A1/en not_active Ceased
- 2009-03-04 MX MX2010009844A patent/MX2010009844A/es not_active Application Discontinuation
- 2009-03-04 CN CN2009801164839A patent/CN102014910A/zh active Pending
- 2009-03-04 US US12/920,400 patent/US20110002989A1/en not_active Abandoned
- 2009-03-04 BR BRPI0909818A patent/BRPI0909818A2/pt not_active IP Right Cessation
- 2009-03-04 EP EP09717510A patent/EP2280711A1/en not_active Withdrawn
- 2009-03-04 AU AU2009220925A patent/AU2009220925A1/en not_active Abandoned
- 2009-03-04 TW TW098106972A patent/TW200950783A/zh unknown
- 2009-03-06 JP JP2009052853A patent/JP2009215293A/ja not_active Withdrawn
- 2009-03-06 AR ARP090100819A patent/AR070964A1/es not_active Application Discontinuation
-
2010
- 2010-08-18 ZA ZA2010/05905A patent/ZA201005905B/en unknown
- 2010-08-24 IL IL207792A patent/IL207792A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110002989A1 (en) | 2011-01-06 |
| WO2009109844A1 (en) | 2009-09-11 |
| JP2009215293A (ja) | 2009-09-24 |
| IL207792A0 (en) | 2010-12-30 |
| BRPI0909818A2 (pt) | 2015-10-06 |
| CA2719115A1 (en) | 2009-09-11 |
| ZA201005905B (en) | 2011-11-30 |
| AU2009220925A1 (en) | 2009-09-11 |
| EP2280711A1 (en) | 2011-02-09 |
| MX2010009844A (es) | 2010-09-30 |
| RU2010135831A (ru) | 2012-04-20 |
| KR20100131477A (ko) | 2010-12-15 |
| TW200950783A (en) | 2009-12-16 |
| CN102014910A (zh) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070964A1 (es) | Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento | |
| CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2012000348A1 (es) | Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica. | |
| CY1119140T1 (el) | Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους | |
| CL2008001966A1 (es) | Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques. | |
| CY1118956T1 (el) | Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης | |
| AR078846A1 (es) | Composicion para el tratamiento de la enfermedad de alzheimer | |
| CO6270302A2 (es) | Formulaciones solidas de liberacion rapida que incluyen florfenicol y sales farmaceuticamente aceptables del mismo. | |
| CL2008003827A1 (es) | Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia.. | |
| AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
| MX2011013467A (es) | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). | |
| TN2009000292A1 (en) | Formulations for cancer treatment | |
| CO6361914A2 (es) | Composición farmacéutica sólida que comprende amlodipina y losartan y proceso para la producción de la misma | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| PE20060588A1 (es) | Composiciones farmaceuticas que contienen flibanserina | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| MX2016014771A (es) | Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
| MX2019015733A (es) | Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| PA8853801A1 (es) | Composición de liberación pulsátil de sildenafil y proceso para prepararla |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |